



# Active Bacterial Core Surveillance (ABCs) Report

## Emerging Infections Program Network

### *Neisseria meningitidis*, 2018



#### ABCs Areas

California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia; Maryland; Minnesota; New Mexico; New York (15 county Rochester and Albany areas); Oregon; Tennessee (20 counties)

#### ABCs Population

The surveillance areas represent 44,817,242 persons.  
Source: National Center for Health Statistics bridged-race vintage 2018 postcensal file

#### ABCs Case Definition

Meningococcal disease: isolation of *Neisseria meningitidis* from normally sterile site in a resident of a surveillance area in 2018.

#### ABCs Methodology

ABCs personnel routinely contacted all microbiology laboratories serving acute care hospitals in their area to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Serogrouping of meningococcal isolates was done at CDC and state laboratories. Regular laboratory audits assessed completeness of active surveillance and detected additional cases.

All rates of meningococcal disease were calculated using population estimates for 2018 from the bridged-race vintage 2018 postcensal file. For national estimates of cases and deaths, race- and age-specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the 2018 U.S. population for 49 states (excluding Oregon due to higher reported incidence rates of serogroup B and overall meningococcal disease). The Oregon reported cases were then added to obtain the national estimates. Cases with missing data, excluding ethnicity, were multiply imputed using sequential regression imputation methods.<sup>¶</sup>

#### Reported ABCs Profiles

Race	No.	(Rate <sup>*</sup> )
Black	14	(0.17)
White	35	(0.11)
Other	3	(0.08)
<b>Total</b>	<b>52</b>	<b>(0.12)</b>

\* Per 100,000 population for ABCs areas

Syndrome	Cases		Deaths	
	No.	(% <sup>*</sup> )	No.	(Rate <sup>†</sup> )
Meningitis	24	(46.2)	2	(8.7)
Bacteremia without focus	16	(30.8)	4	(25.0)

\*Percent of cases

† Per 100 cases with known outcome

#### ¶ Surveillance Note

Missing race (n=6) data were multiply imputed using sequential regression imputation methods.

#### Serogroups

Age (years)	B No. (Rate <sup>*</sup> )	C No. (Rate <sup>*</sup> )	Y No. (Rate <sup>*</sup> )	Other <sup>‡</sup> No. (Rate <sup>*</sup> )
< 1	1 (0.21)	0 (0.00)	0 (0.00)	2 (0.42)
1	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
2-4	2 (0.14)	0 (0.00)	0 (0.00)	0 (0.00)
5-17	0 (0.00)	0 (0.00)	0 (0.00)	1 (0.02)
18-34	1 (0.01)	1 (0.01)	1 (0.01)	3 (0.03)
35-49	2 (0.03)	2 (0.03)	3 (0.04)	4 (0.05)
50-64	3 (0.04)	0 (0.00)	5 (0.06)	2 (0.03)
65-74	0 (0.00)	1 (0.03)	1 (0.03)	1 (0.03)
75-84	1 (0.06)	0 (0.00)	1 (0.06)	0 (0.00)
≥ 85	0 (0.00)	0 (0.00)	1 (0.13)	0 (0.00)
<b>Total †</b>	<b>10 (0.02)</b>	<b>4 (0.01)</b>	<b>12 (0.03)</b>	<b>13 (0.03)</b>

\* Per 100,000 population for ABCs areas excluding Oregon

† Unknown serogroup (n=4) distributed amongst known.

All rates exclude Oregon. Rates including Oregon are serogroup B 0.03, serogroup C 0.03, serogroup Y 0.03, and serogroup Other 0.03 per 100,000 population for ABCs areas.

‡ Other includes serogroup W and nongroupables

#### Rates of Meningococcal Disease in Adolescents and Young Adults<sup>†</sup>

Age (years)	Overall Serogroups		C/Y/W Serogroups	
	No.	(Rate <sup>*</sup> )	No.	(Rate <sup>*</sup> )
11-17	1	(0.03)	0	(0.00)
18-22	1	(0.04)	0	(0.00)

\* Per 100,000 population for ABCs areas excluding Oregon

† All rates exclude Oregon. Rates including Oregon are, for 11-17 year olds, overall serogroups 0.05 and serogroup C/Y/W 0.03; for 18-22 year olds, overall serogroups 0.03 and serogroup C/Y/W 0.00 per 100,000 population for ABCs areas

#### National Estimates for Disease<sup>‡</sup>

Cases: 310 (0.09/100,000)  
Deaths: 50 (0.02/100,000)

‡ In 2018, 329 cases of meningococcal disease (confirmed and probable) were reported to the National Notifiable Disease Surveillance System, resulting in an incidence of 0.10/100,000 population. For additional information on national incidence, please view our Enhanced Meningococcal Disease Surveillance Report: <https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2018.pdf>

#### Healthy People 2020 Update

Objective: Reduce the incidence of meningococcal disease to 0.3 per 100,000 population.

2020 Objective	2018 Rate <sup>*</sup>
0.3/100,000	0.09/100,000

\* Per 100,000 U.S. population

For more information, visit our web site:

<http://www.cdc.gov/abcs>

#### Citation

Centers for Disease Control and Prevention. 2018. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2018. Available via the Internet: <http://www.cdc.gov/abcs/reports-findings/surveys/mening18.pdf>